Till Sebastian Clauditz1, Arne Böttcher2, Henning Hanken3, Kerstin Borgmann4, Guido Sauter5, Waldemar Wilczak5, Tobias Grob6, Adrian Münscher2. 1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. t.clauditz@uke.de. 2. Department of Oto-, Rhino, Laryngology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 3. Department of Oral and Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 4. Department of Radiation-Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 5. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. 6. Institute of Pathology, University Bern, Hochschulstrasse 6, 3012, Bern, Switzerland.
Abstract
BACKGROUND: FGFR1 is a receptor tyrosine kinases involved in tumor growth signaling, survival, and differentiation in many solid cancer types. There is growing evidence that FGFR1 amplification might predict therapy response to FGFR1 inhibitors in squamous cell lung cancers. To estimate the potential applicability of anti FGFR1 therapies in squamous cell carcinomas of the head and neck, we studied patterns of FGFR1 amplification using fluorescence in situ hybridization (FISH). MATERIALS AND METHODS: A tissue microarray was constructed from 453 primary treatment-naive squamous cell carcinomas of the head and neck regions with histopathological and clinical follow-up data [including oral cavity (n = 222), oropharynx (n = 126), and larynx (n = 105)]. FGFR1 and centromere 8 copy numbers were assessed by dual-color FISH. FGFR1 amplification was defined as a copy number ratio FGFR1: centromere 8 ≥ 2.0. HPV sequencing and p16 immunohistochemistry (IHC) were applied to FGFR1-amplified cancers. RESULTS: FISH analysis was successful in 297 (66%) of the 453 cancers. FGFR1 amplification was found in 6% of analyzable tumors, and was more frequent in tumors of the oral cavity (13/133 amplified, 10%), than cancers of other localizations (1/79 oropharynx, 4/85 larynx; p = 0.007 and 0.159, respectively). One out of 18 FGFR1 amplified cancers was HPV positive. No associations were found between FGFR1 amplification and tumor phenotype or p16 IHC. CONCLUSIONS: Head and neck cancers are recurrently affected by FGFR1 amplification, with a predominance in cancers of the oral cavity. Finding only one HPV positive and FGFR1 amplified cancer argues against a causal relationship between HPV and FGFR1 amplifications.
BACKGROUND: FGFR1 is a receptor tyrosine kinases involved in tumor growth signaling, survival, and differentiation in many solid cancer types. There is growing evidence that FGFR1 amplification might predict therapy response to FGFR1 inhibitors in squamous cell lung cancers. To estimate the potential applicability of anti FGFR1 therapies in squamous cell carcinomas of the head and neck, we studied patterns of FGFR1 amplification using fluorescence in situ hybridization (FISH). MATERIALS AND METHODS: A tissue microarray was constructed from 453 primary treatment-naive squamous cell carcinomas of the head and neck regions with histopathological and clinical follow-up data [including oral cavity (n = 222), oropharynx (n = 126), and larynx (n = 105)]. FGFR1 and centromere 8 copy numbers were assessed by dual-color FISH. FGFR1 amplification was defined as a copy number ratio FGFR1: centromere 8 ≥ 2.0. HPV sequencing and p16 immunohistochemistry (IHC) were applied to FGFR1-amplified cancers. RESULTS: FISH analysis was successful in 297 (66%) of the 453 cancers. FGFR1 amplification was found in 6% of analyzable tumors, and was more frequent in tumors of the oral cavity (13/133 amplified, 10%), than cancers of other localizations (1/79 oropharynx, 4/85 larynx; p = 0.007 and 0.159, respectively). One out of 18 FGFR1 amplified cancers was HPV positive. No associations were found between FGFR1 amplification and tumor phenotype or p16 IHC. CONCLUSIONS: Head and neck cancers are recurrently affected by FGFR1 amplification, with a predominance in cancers of the oral cavity. Finding only one HPV positive and FGFR1 amplified cancer argues against a causal relationship between HPV and FGFR1 amplifications.
Authors: Fabrice André; Thomas Bachelot; Mario Campone; Florence Dalenc; Jose M Perez-Garcia; Sara A Hurvitz; Nicholas Turner; Hope Rugo; John W Smith; Stephanie Deudon; Michael Shi; Yong Zhang; Andrea Kay; Diana Graus Porta; Alejandro Yovine; José Baselga Journal: Clin Cancer Res Date: 2013-05-08 Impact factor: 12.531
Authors: Marianne E Marshall; Trista K Hinz; Scott A Kono; Katherine R Singleton; Brady Bichon; Kathryn E Ware; Lindsay Marek; Barbara A Frederick; David Raben; Lynn E Heasley Journal: Clin Cancer Res Date: 2011-06-14 Impact factor: 12.531
Authors: Jonathan A Ledermann; Allan Hackshaw; Stan Kaye; Gordon Jayson; Hani Gabra; Iain McNeish; Helena Earl; Tim Perren; Martin Gore; Mojca Persic; Malcolm Adams; Lindsay James; Graham Temple; Michael Merger; Gordon Rustin Journal: J Clin Oncol Date: 2011-08-22 Impact factor: 44.544
Authors: Xavier Castellsagué; Maria Jesús Quintana; Maria Carmen Martínez; Adoración Nieto; Maria José Sánchez; Amparo Juan; Antoni Monner; Marta Carrera; Antoni Agudo; Miquel Quer; Nubia Muñoz; Rolando Herrero; Silvia Franceschi; F Xavier Bosch Journal: Int J Cancer Date: 2004-02-20 Impact factor: 7.396
Authors: Jorge Sergio Reis-Filho; Pete T Simpson; Nicholas C Turner; Maryou Ballo Lambros; Chris Jones; Alan Mackay; Anita Grigoriadis; David Sarrio; Kay Savage; Tim Dexter; Marjan Iravani; Kerry Fenwick; Barbara Weber; David Hardisson; Fernando Carlos Schmitt; Jose Palacios; Sunil R Lakhani; Alan Ashworth Journal: Clin Cancer Res Date: 2006-11-15 Impact factor: 12.531
Authors: May P Chan; Komal R Plouffe; Chia-Jen Liu; Nallasivam Palanisamy; Shannon Carskadon; Lili Zhao; Rosalynn M Nazarian; Alison B Durham; Timothy M Johnson; Aleodor A Andea; Rajiv M Patel; Lori Lowe; Douglas R Fullen; Noah A Brown; Scott A Tomlins; Aaron M Udager; Paul W Harms Journal: Mod Pathol Date: 2019-12-19 Impact factor: 7.842
Authors: Genevieve Stein-O'Brien; Luciane T Kagohara; Sijia Li; Manjusha Thakar; Ruchira Ranaweera; Hiroyuki Ozawa; Haixia Cheng; Michael Considine; Sandra Schmitz; Alexander V Favorov; Ludmila V Danilova; Joseph A Califano; Evgeny Izumchenko; Daria A Gaykalova; Christine H Chung; Elana J Fertig Journal: Genome Med Date: 2018-05-23 Impact factor: 11.117
Authors: Malte Kriegs; Till Sebastian Clauditz; Konstantin Hoffer; Joanna Bartels; Sophia Buhs; Helwe Gerull; Henrike Barbara Zech; Lara Bußmann; Nina Struve; Thorsten Rieckmann; Cordula Petersen; Christian Stephan Betz; Kai Rothkamm; Peter Nollau; Adrian Münscher Journal: Sci Rep Date: 2019-09-19 Impact factor: 4.379